SK Biopharmaceuticals Co., Ltd.
326030
शेयरों में रैंक
#4037
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
शेयर मूल्य
$51.65
मार्केट कैप
$4.05B
बदलाव (1 दिन)
0.27%
बदलाव (1 वर्ष)
-30.95%
देश
KR
व्यापार SK Biopharmaceuticals Co., Ltd. (326030)
श्रेणी
Healthcare
SK Biopharmaceuticals Co., Ltd. (326030) के लिए P/B अनुपात
October 2026 को P/B अनुपात TTM: 5.32
SK Biopharmaceuticals Co., Ltd. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 5.32 है। 2024 के अंत में, कंपनी का P/B अनुपात 15.93 था।
SK Biopharmaceuticals Co., Ltd. के लिए 2011 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
| वर्ष | P/B अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 5.32 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.93 | -44.04% |
| 2023 | 28.46 | 61.13% |
| 2022 | 17.66 | 3.07% |
| 2021 | 17.14 | -46.44% |
| 2020 | 32.00 | -105.05% |
| 2019 | -633.75 | -570.11% |
| 2018 | 134.81 | 0.30% |
| 2017 | 134.41 | 212.50% |
| 2016 | 43.01 | 22.07% |
| 2015 | 35.23 | 21.42% |
| 2014 | 29.02 | -14.39% |
| 2013 | 33.89 | 23.27% |
| 2012 | 27.50 | 16.93% |
| 2011 | 23.51 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
| कंपनी | P/B अनुपात | P/B अनुपात में अंतर | देश |
|---|---|---|---|
| 6.251 | 17.52% |
US
|
|
| 13.2547 | 149.19% |
US
|
|
| 4.208 | -20.89% |
AU
|
|
| 6.1824 | 16.23% |
NL
|
|
| - | - |
CH
|
